AcelRx Pharmaceuticals (ACRX) Reports In-Line Q3 Loss of 38c/Share

November 6, 2012 4:12 PM

AcelRx Pharmaceu

ticals (NASDAQ: ACRX) reported Q3 EPS of ($0.38), in-line with the analyst estimate of ($0.38). Revenue for the quarter came in at $166 thousand versus the consensus estimate of $320 thousand.

For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.